

Acceptance and concerns regarding COVID-19 vaccine in Kerala, India

Anamika Anil¹, Sulthana Sharafudeen¹, Anjali Krishna¹, Revathy Rajendran¹, Jesline M. James¹, Suneesh Kuruvilla¹, Subramaniam Ramanarayanan¹

AFFILIATION

¹ Indira Gandhi Institute of Dental Sciences, Kerala, India

CORRESPONDENCE TO

Subramaniam Ramanarayanan. Indira Gandhi Institute of Dental Sciences, Kothamangalam, Nellikuzhi P.O. 686 691, Kerala, India. E-mail: subbds@gmail.com ORCID ID: <https://orcid.org/0000-0003-2863-6708>

KEYWORDS

vaccination, SARS-CoV-2, COVID-19, vaccination hesitancy

Received: 11 August 2021, **Accepted:** 6 September 2021

Public Health Toxicol 2021;1(1):5

<https://doi.org/10.18332/pht/141976>

ABSTRACT

INTRODUCTION The current global pandemic of COVID-19 is an international threat. A safe and effective vaccine for COVID-19 infection has been on the wish list of healthcare agencies across the globe since the onset of the pandemic. As the process of development of vaccine demands clinical trials across various phases for multiple checks concerning its safety, potency, and efficacy, there is an inherent delay in its launch. Considering the immediate need for global vaccination, the currently administered vaccines have been developed with a short period of testing and hence is a matter of concern among the population. Thus, this study was conducted to assess the acceptance and concerns regarding the vaccinations in the Indian state of Kerala.

METHODS The study was a cross-sectional questionnaire-based survey conducted online. The target population was individuals aged ≥ 18 years. The questionnaire was divided into two parts. The first part consisted of questions on personal data such as age, gender, education level, and

occupation. The second part consisted of 10 questions to assess the willingness and concerns regarding vaccination for COVID-19 infection.

RESULTS The final sample size comprised 314 participants. Over 92% indicated that they were aware of the vaccination guidelines. About 42% reported to have received knowledge about vaccination through printed media and 55% through social media. Among the 84% who were willing to take vaccination or already vaccinated, 39% expressed their willingness to get vaccinated due to their trust in the government's awareness campaigns. Among 16% unwilling to take the vaccine, 86% were anxious about the side effects/adverse reactions of the vaccine, and 56% were anxious regarding the effectiveness of the vaccine.

CONCLUSIONS The study reveals a good level of acceptance regarding vaccination acceptance among the population studied. The predominant concerns regarding the vaccine included adverse reactions and efficacy. The study population demonstrated a positive attitude towards vaccination.

INTRODUCTION

The current global pandemic of COVID-19 is an international threat¹. As of 28 April 2021, the COVID-19 has rapidly spread across the globe with high morbidity and mortality, currently affecting over 149 million people and claiming over 3 million lives². India is currently the second most affected country in the world after the United States³. Apart from effective treatments, vaccination is a key preventive strategy in mitigating the pandemic¹.

A vaccine that is safe and effective for COVID-19 infection has been on the wish list of healthcare agencies across

the globe, since the onset of the pandemic. As the process of development of vaccine demands clinical trials across various phases for multiple checks about its safety, potency, and efficacy, there is an inherent delay in its launch. The vaccine needs to be tested among all groups of individuals, particularly in high-risk individuals such as the elderly, pregnant women, and people with co-morbidities, and immunodeficiencies⁴.

India started the administration of vaccines for COVID-19, on 16 January with a focus on India's healthcare workers and frontline workers. Later, in a phased manner, the vaccination

drive extended to senior citizens and those ≥ 45 years with co-morbidities. From 1 May 2021 onwards, those aged >18 years were to be eligible. India is currently administering two vaccines – one developed by AstraZeneca with Oxford University (Covishield) and one by the Indian firm Bharat Biotech (Covaxin) – both of which were approved in January 2021, ahead of the vaccine rollout. In April 2021, a third vaccine – Russia's Sputnik V – was approved for use⁵.

Normally, it takes years for the development of a safe and effective vaccine. Considering the immediate need for vaccination, the currently administered vaccines have been developed with a short period of testing and hence is a matter of concern among the population⁶⁻⁸. This concern over the safety and efficacy, resulting in vaccine hesitancy, is a potential barrier to effective implementation of vaccination programs⁶. Thus, this study was conducted to assess the acceptance and concerns regarding vaccinations in the Indian state of Kerala.

METHODS

Study design, target population and questionnaire

This study was an observational questionnaire-based study. The study was conducted among individuals aged ≥ 18 years. A questionnaire was developed in English, translated into the local language Malayalam and was validated for face validity by distributing the questionnaire to subject experts with proficiency in Malayalam. It was divided into two parts. Part A consisted of sociodemographic information and Part B contained 10 questions on assessment willingness and concerns regarding vaccination for COVID-19 infection.

Data collection

The data collection was done for one week in April 2021. The data were collected by the principal investigator through the distribution of questionnaires, as well as through online mode using Google forms. A convenient sampling technique was used. The study protocol was approved by the Ethics Committee of the Indira Gandhi Institute of Dental Sciences, Kerala. All participants provided informed consent before data collection.

Statistical analysis

The obtained data were coded and tabulated and analyzed using Statistical Package for Social Sciences (SPSS) Version 16.0 for Windows. Descriptive statistics were expressed as frequencies and percentages. Inferential analysis was done using the chi-squared test for the independent variables. A p-value less than 0.05 was considered statistically significant.

RESULTS

A total of 318 participants responded, of whom 4 were not willing to participate in the survey. The final sample size comprised 314 participants, a response rate of 98.74%. Table 1 shows the profile of the respondents. About 44.6% were males and 55.4% were females, and about 72% were graduates and postgraduates.

Table 2 shows the response to the concerns and willingness regarding vaccination for COVID-19. Over 92% indicated that they were aware of the vaccination guidelines. About 42% obtained information about vaccination through printed media, 55% through social media, and 27% through healthcare professionals. Over 52% reported having taken the first or second dose of the vaccine, and 16% were not willing to take the vaccine. Among the 84% who were willing to take vaccination or

Table 1. Profile of the respondents

| Characteristic | n (%) |
|------------------------|-------------|
| Gender | |
| Male | 140 (44.58) |
| Female | 174 (55.42) |
| Education level | |
| Middle school | 9 (2.87) |
| High school | 21 (6.69) |
| Pre-degree/diploma | 57 (18.15) |
| Graduate | 170 (54.14) |
| Postgraduate | 57 (18.15) |

Table 2. Response to questions assessing the willingness and concerns regarding COVID-19 vaccine

| Questions | Options | Responses n (%) | χ^2 |
|------------------------------------------------------------|--------------------------|-----------------|-------------------------------------|
| Are you aware of COVID-19 vaccine? | Yes | 289 (92.03) | 0.414 (gender) 0.130 (education) |
| | No | 25 (7.97) | |
| What was your source of information regarding the vaccine? | Print media | 133 (42.35) | 0.839 (gender) 0.120 (education) |
| | Social media | 174 (55.41) | |
| | Radio/visual media | 113 (35.98) | |
| | Healthcare professionals | 86 (27.38) | |
| | Peers | 56 (17.83) | |

Continued

Table 2. Continued

| Questions | Options | Responses n (%) | χ^2 |
|-----------------------------------------------------------------------------|-------------------------------------------|-----------------|-------------------------------------|
| Are you willing to take the vaccine at the earliest available date? | Yes | 220 (70.06) | 0.130 (gender) 0.312 (education) |
| | No | 53 (24.76) | |
| | Already vaccinated | 41 (13.06) | |
| If yes, what is the reason for taking vaccine | Advise from relatives and friends | 23 (8.81) | 0.150 (gender) 0.682 (education) |
| | Advice from healthcare professionals | 73 (27.96) | |
| | Government's awareness campaigns | 103 (39.46) | |
| | Fear of contracting the disease | 76 (29.11) | |
| | Job related exposure | 59 (22.60) | |
| | Mandatory instructions from employers | 31 (11.87) | |
| | Travel related reasons | 12 (4.59) | |
| | Ease of getting vaccines | 2 (0.7) | |
| If no, what is the reason? | Not eligible for vaccinations | 11 (20.75) | 0.459 (gender) 0.408 (education) |
| | Low risk of disease | 10 (18.86) | |
| | Let the infection naturally come and go | 5 (9.43) | |
| | Lack of trust in the present vaccines | 14 (26.41) | |
| | Fear of injection | 11 (20.75) | |
| | Media influence | 4 (7.54) | |
| | Anxious about adverse reaction | 46 (86.79) | |
| | Anxious about the efficacy of vaccines | 30 (56.60) | |
| | Fear of long-term complications | 8 (15.09) | |
| | Active/recovered from the disease | 7 (13.80) | |
| | Logistic difficulties | 2 (3.77) | |
| | Expense pertaining to vaccine | 13 (24.52) | |
| | Will you motivate others for vaccination? | Yes | |
| No | | 34 (11.46) | |
| After vaccination, are you ready to follow necessary preventive measures? | Yes | 309 (98.41) | 0.214 (gender) 0.653 (education) |
| | No | 5 (1.59) | |
| Are you willing to participate in awareness programs on COVID-19 infection? | Yes | 222 (70.70) | 0.531 (gender) 0.447 (education) |
| | No | 92 (29.30) | |

who were already vaccinated, over 39% expressed that their willingness in getting vaccination was due to their trust in the government's awareness campaigns, 29% due to fear of contracting the disease, and 27% due to instructions from healthcare professionals. Among 16% unwilling to take the vaccine, over 86% were anxious about the side effects/

adverse reactions of the vaccine, and over 56% were anxious regarding the effectiveness of the vaccine. More than 88% of the respondents were willing to recommend vaccination to others, and more than 98% were ready to follow COVID-19 prevention protocols even after vaccination. About 30% were not willing to participate in COVID-19 awareness programs.

There was no significant difference in any response in relation to gender and education level.

DISCUSSION

Vaccination is considered the most significant achievement in public health⁹. Vaccination is regarded as one of the game-changing health sector interventions of the 21st century. Despite its benefits, this fundamental health-protecting tool is facing many obstacles globally⁶.

Several COVID-19 vaccines have now been authorized or approved for human use, and many more are currently in the late stages of development and research. However, having licensed vaccines is not enough to achieve global control of COVID-19; they also need to be produced on an immense scale, priced affordably, and allocated globally so that they are available where and when required. These four dimensions of the global vaccination challenge are closely interrelated¹⁰. Nonetheless, yet another major challenge is public confidence and acceptance.

Many factors like geography, time, social class, contextual human behavior, and ethnicity are affecting public confidence and acceptance of vaccination¹¹. Studies report that public perception of the benefits and relative risks of vaccination is a major obstacle for vaccine acceptance⁶.

To be successful in reducing the prevalence and incidence of vaccine-preventable diseases (VPD), vaccination programs rely on a high uptake level. In addition to offering direct protection for vaccinated individuals, vaccination contributes indirectly to herd immunity by slowing the transmission⁹. Concerning COVID-19 disease, an effective vaccination against SARS-CoV-2 infection could mobilize the innate and adaptive immune responses and protect against severe forms of the disease. The SARS-CoV-2 virus can undergo mutations and can change antigenically over time. This may lead to only seasonal protection from the COVID-19 vaccine. The vaccination may thus not eradicate the disease. However, it can decrease the mortality and morbidity of the disease¹².

This study was conducted to assess the public's acceptance and concerns regarding vaccination against COVID-19 disease. The study was set during a period when large clinical trials have shown remarkable promise about efficacy without worrying about safety signals. However, due to the fast-tracking of research related to these vaccines, there is still concern regarding the scientific review, safety, and effectiveness, all of which have increased the hesitancy towards vaccination¹³. The causes of vaccine hesitancy, as reported in different studies, include religious reasons, personal beliefs, and safety concerns due to widespread myths, including the association of vaccines and autism, brain damage, and other conditions¹⁴. Unfortunately, in the Kerala state of India, insufficient studies have been conducted to assess the local population's attitudes toward vaccination.

It is noteworthy that over 92% of the respondents were aware of vaccine guidelines for COVID-19. The observation contrasts with the results of the study conducted among

urban slum dwellers in Mumbai, where only 9% were aware. The probable reason could be the increased rate of illiteracy (>30%) and the time of conduct of the previous study (October 2020)⁴.

More than 55% of the respondents noted that they received information regarding the COVID-19 vaccine through social media and over 42% through printed media. With the highest literacy levels in India, Kerala state enjoys the maximum reach in regard to social and print media^{15,16}.

Over 83% of the respondents were either already vaccinated (13%) or expressed their willingness to get vaccinated against COVID-19 at the earliest available date (70%). The observation is similar to studies conducted in the USA (80%)¹⁷ and India (86.3%)⁶. The figure obtained in our study is higher compared to China (72.5%)¹⁸, South Africa (64%), Russia (54%), France (59%), Poland (56%), and Hungary (56%)^{19,20}. The results of this study also parallel the finding of the IPSOS survey, where the vaccine acceptance rate was 87% among the Indian population¹⁹.

Among those willing to take the vaccine, the most common reasons cited for their willingness (in decreasing order of frequency) were: trust in government vaccination campaigns (39.46%), fear of contracting the disease (29.11%), advice from healthcare professionals (27.96%), occupation related risks (22.60%), mandatory instructions from employers (11.87%), advice from relatives and friends (8.81%), and travel-related reasons (4.59%). In a study conducted among students of a university in China, perceived severity of COVID-19 was positively associated with motivation to have COVID-19 vaccination. Receiving information concerning COVID-19 vaccination from medical personnel was associated with greater self-efficacy, response efficacy, and knowledge, whereas receiving information concerning COVID-19 vaccination from co-workers/colleagues was associated with less response efficacy and knowledge²¹.

The major barriers/reasons for hesitancy reported by those unwilling to take the vaccine (in decreasing order of frequency) were: anxiety about adverse reactions, concern regarding the efficacy of vaccine, lack of trust in vaccines, cost of vaccines, and fear of injection. In another study conducted in India in 2020, the majority were concerned about COVID-19 vaccine side effects, and 20.2% of the respondents lacked confidence in the effectiveness of vaccination⁶. Anxiety about adverse reactions appears to be the most common reason for hesitancy in the majority of the studies^{4,6,17,20,22}.

Vaccine hesitancy is a major obstacle that needs to be overcome for controlling a pandemic such as COVID-19. The World Health Organization (WHO) has identified vaccine hesitancy as a leading global health threat²³. Hesitancy towards vaccination has been reported previously and the main reasons for hesitancy include the compulsory nature of vaccines, their coincidental temporal relationships to adverse health outcomes, religious reasons, unfamiliarity

with vaccine-preventable diseases, and lack of trust in corporations and public health agencies²⁴. The concerns regarding adverse reactions and efficacy can only be addressed with evidence-based research. Mass, credible awareness programs can help in increasing the acceptance of the vaccine.

CONCLUSIONS

The study reveals a good level of acceptance regarding vaccination acceptance among the population studied. The predominant concerns regarding the vaccine included adverse reactions and efficacy. The study population demonstrated a positive attitude towards vaccination. Further studies with larger representative sample sizes are needed to assess future uptake and potential changes in vaccination uptake/hesitancy in Kerala, India.

REFERENCES

- Harapan H, Wagner AL, Yufika A, et al. Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia. *Hum Vaccin Immunother.* 2020;16(12):3074-3080. doi:10.1080/21645515.2020.1819741
- COVID-19 CORONAVIRUS PANDEMIC. worldometer.info. Updated September 7, 2021. Accessed April 28, 2021. <https://web.archive.org/web/20210428035209/https://www.worldometers.info/coronavirus/>
- COVID19 India. covid19india.org. Accessed April 28, 2021. <https://web.archive.org/web/20210428020502/https://www.covid19india.org/>
- Bhartiya S, Kumar N, Singh T, Murugan S, Rajavel S, Wadhvani M. Knowledge, attitude and practice towards COVID-19 vaccination acceptance in West India. *Int J Community Med Public Health.* 2021;8(3):1170. doi:10.18203/2394-6040.ijcmph20210481
- Covid-19 vaccination: How is India's inoculation drive going. *BBC News*. Published April 20, 2021. Accessed April 30, 2021. <https://web.archive.org/web/20210430142952/https://www.bbc.com/news/world-asia-india-56345591>
- Sharun K, Faslur Rahman CK, Haritha CV, Jose B, Tiwari R, Dhama K. COVID-19 VACCINE ACCEPTANCE: BELIEFS AND BARRIERS ASSOCIATED WITH VACCINATION AMONG THE GENERAL POPULATION IN INDIA. *Journal of Experimental Biology and Agricultural Sciences.* 2020;8(Spl-1- SARS-CoV-2):S210-S218. doi:10.18006/2020.8(Spl-1-SARS-CoV-2).S210.S218
- Rabaan AA, Al-Ahmed SH, Sah R, et al. SARS-CoV-2/ COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. *Ann Clin Microbiol Antimicrob.* 2020;19(1):40. doi:10.1186/s12941-020-00384-w
- Patel SK, Pathak M, Tiwari R, et al. A vaccine is not too far for COVID-19. *J Infect Dev Ctries.* 2020;14(5):450-453. doi:10.3855/jidc.12744
- Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. *Hum Vaccin Immunother.* 2013;9(8):1763-1773. doi:10.4161/hv.24657
- Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. *Lancet.* 2021;397(10278):1023-1034. doi:10.1016/S0140-6736(21)00306-8
- Larson HJ, Clarke RM, Jarrett C, et al. Measuring trust in vaccination: A systematic review. *Hum Vaccin Immunother.* 2018;14(7):1599-1609. doi:10.1080/21645515.2018.1459252
- Strizova Z, Smetanova J, Bartunkova J, Milota T. Principles and Challenges in anti-COVID-19 Vaccine Development. *Int Arch Allergy Immunol.* 2021;182(4):339-349. doi:10.1159/000514225
- The COVID vaccine challenges that lie ahead. *Nature.* 2020;587(7835):522. doi:10.1038/d41586-020-03334-w
- Al-Qerem WA, Jarab AS. COVID-19 Vaccination Acceptance and Its Associated Factors Among a Middle Eastern Population. *Front Public Health.* 2021;9:632914. doi:10.3389/fpubh.2021.632914
- Suresh A, George N, Karthika C. SOCIAL MEDIA PLATFORM AS A MAINSTREAM NEWS IN KERALA: A CASE STUDY ON INSTAGRAM AS A SOCIAL MEDIA PLATFORM. *International Journal of Psychosocial Rehabilitation.* 2020;24(8):10119-10132. doi:10.37200/IJPR/V24I8/PR281006
- Print continues to be the strongest medium in Kerala. exchange4media.com. Updated April 19, 2021. Accessed May 16, 2021. <https://www.exchange4media.com/media-print-news/print-continues-to-be-the-strongest-medium-in-kerala-112401.html>
- Thunstrom L, Ashworth M, Finnoff D, Newbold S. Hesitancy Towards a COVID-19 Vaccine and Prospects for Herd Immunity. *SSRN Electronic Journal.* 2020:1-51. doi:10.2139/ssrn.3593098
- Fu C, Wei Z, Pei S, Li S, Sun X, Liu P. Acceptance and preference for COVID-19 vaccination in healthcare workers (HCWs). *medRxiv*. Preprint posted online April 14, 2020. doi:10.1101/2020.04.09.20060103
- Three in four adults globally say they would get a vaccine for COVID-19. ipsos.com. September 1, 2020. Accessed May 16, 2021. <https://www.ipsos.com/ipsos-mori/en-uk/three-four-adults-globally-say-they-would-get-vaccine-covid-19>
- Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med.* 2021;27(2):225-228. doi:10.1038/s41591-020-1124-9
- Wang PW, Ahorsu DK, Lin CY, et al. Motivation to Have COVID-19 Vaccination Explained Using an Extended Protection Motivation Theory among University Students in China: The Role of Information Sources. *Vaccines (Basel).* 2021;9(4):380. doi:10.3390/vaccines9040380
- Dodd RH, Pickles K, Nickel B, et al. Concerns and motivations about COVID-19 vaccination. *Lancet Infect Dis.* 2021;21(2):161-163. doi:10.1016/S1473-3099(20)30926-9v
- Four reasons for COVID-19 vaccine hesitancy among health care workers, and ways to counter them. aafp.org. April 27, 2021. Accessed May 22, 2021. https://www.aafp.org/journals/fpm/blogs/inpractice/entry/countering_vaccine_hesitancy.html

24. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine Hesitancy: Causes, Consequences, and a Call to Action. *Am J Prev Med.* 2015;49(6):S391-S398. doi:10.1016/j.amepre.2015.06.009

CONFLICTS OF INTEREST

The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.

FUNDING

There was no source of funding for this research.

ETHICAL APPROVAL AND INFORMED CONSENT

The study protocol was approved by the Ethics Committee of the Indira Gandhi Institute of Dental Sciences, Kerala. All participants provided informed consent before data collection.

DATA AVAILABILITY

The data supporting this research are available from the authors on reasonable request.

PROVENANCE AND PEER REVIEW

Not commissioned; externally peer reviewed.